Carl Byrnes

Ashwani Verma

Balaji Prasad

Christopher Uhde

Di Zhao

Niall Alexander

Vineet Agra

- Alvotech's commercialization partner in Japan, Fuji Pharma Co., Ltd., received marketing authorization for **three new biosimilars**: AVT03 (referencing Xgeva/Ranmark), AVT05 (referencing Simponi), and AVT06 (referencing Eylea).  **[1898416_0001171843-25-006012_f6k_092225.htm:0]** **[1898416_0001171843-25-006012_exh_991.htm:0]** 
- **AVT05** is the **first golimumab biosimilar** to be approved for sale in major markets globally.  **[1898416_0001171843-25-006012_exh_991.htm:0]** 
- These approvals, announced on **September 19, 2025**, expand Alvotech's presence in Japan, following the successful launch of a Stelara biosimilar in **May 2024** with Fuji Pharma.  **[1898416_0001171843-25-006012_f6k_092225.htm:0]** **[1898416_0001171843-25-006012_exh_991.htm:0]**

Alvotech (ALVO)